Interestingly, our results indicated that FXR can impede the generation and secretion of tumor Exos, and an FXR agonist can inhibit the increased expression of PD-L1 on N-Exos while restoring the modulation of CD4+ T cells by N-Exos. The gene discussed is NR1H4; the disease is neoplasm.